PT  - JOURNAL ARTICLE
AU  - Summers, Jaye
ED  - Hauser, Steven
TI  - Baseline Features of Patients With RMS in Ocrelizumab Trials OPERA I and OPERA II
DP  - 2015 Jun 20
TA  - MD Conference Express
PG  - 14--14
VI  - 15
IP  - 9
4099  - http://mdc.sagepub.com/content/15/9/14.1.short
4100  - http://mdc.sagepub.com/content/15/9/14.1.full
AB  - OPERA I and OPERA II tested the safety and efficacy of ocrelizumab in patients with relapsing multiple sclerosis. Patients were randomized to either ocrelizumab or interferon beta-1a. At baseline, patient demographics and disease characteristics appear consistent with the majority of patients with the relapsing type of the disease.